DocGo Expands Mobile Health Services with PTI Health Acquisition for Enhanced Patient Care
- DocGo acquires PTI Health to enhance mobile lab services and address barriers to diagnostic care for underserved populations.
- The integration will begin in New York City, improving access to lab services for diverse healthcare needs.
- DocGo aims to support mobile clinical trials and expand its service offerings, reinforcing its commitment to accessible healthcare.
DocGo Expands Mobile Health Services through Strategic Acquisition of PTI Health
DocGo Inc. has recently made a significant move in the mobile health services industry by acquiring PTI Health, a respected mid-Atlantic company specializing in mobile lab collection and phlebotomy services. This acquisition marks a pivotal step for DocGo, allowing it to broaden its healthcare offerings and focus on addressing the needs of underserved populations that often face barriers to accessing traditional diagnostic care. By integrating PTI Health's capabilities, DocGo aims to introduce mobile phlebotomy services that facilitate timely blood collection and at-home testing, thus enhancing patient care and improving overall healthcare accessibility.
The integration of PTI Health into DocGo’s operations is set to begin in New York City, a crucial urban market with a diverse population and varying healthcare needs. CEO Lee Bienstock underscores the importance of this acquisition, highlighting how PTI’s existing relationships with the two largest labs in the U.S. will enable DocGo to provide patients with quicker access to lab services. The strategic move not only enhances DocGo's vertically integrated care model but also strengthens its ability to serve homebound patients and those facing transportation challenges. PTI Health's skilled mobile phlebotomists conduct thousands of lab collections each year, which will now be part of DocGo's expanded service offerings.
Wayne Meadows, the President of PTI Health, will transition to DocGo as General Manager, signaling a commitment to the partnership and a shared vision for improving healthcare delivery. The acquisition complements DocGo's mission, as the company boasts a remarkable mobile health Net Promoter Score (NPS) of 86 for 2024, demonstrating its focus on exceptional patient experiences. Through this acquisition, DocGo endeavors to enhance its service footprint across the U.S., ultimately striving to close critical care gaps and lead the proactive healthcare revolution through innovative solutions.
In addition to expanding its mobile lab services, DocGo's acquisition of PTI Health also positions the company to support mobile clinical trials, further diversifying its healthcare offerings. This capability not only allows DocGo to meet emerging healthcare demands but also aligns with industry trends that emphasize the importance of accessible and convenient healthcare solutions.
Overall, this strategic acquisition is a crucial step for DocGo as it continues to innovate in the mobile health sector and reinforce its commitment to improving healthcare access for all patients, ultimately shaping the future of healthcare delivery in the United States.
Related Cashu News

RadNet Launches AI-Powered Reporting Pro, Enhancing Imaging Services and Financial Growth Strategy
RadNet (Ticker: RDNT) makes a notable advancement in its healthcare strategy with the recent launch of Reporting Pro, an innovative AI-powered radiology reporting platform that aims to transform the d…

HealthEquity Reports Strong Q1 Growth Amid AI Integration and Cybersecurity Challenges
HealthEquity (Ticker: HQY) reports substantial growth in its recent fiscal 2027 first-quarter results, highlighting advancements in Health Savings Accounts and total assets under management. The compa…

UFP Technologies Appoints New Leadership Team to Drive Strategic Growth and Innovation
UFP Technologies (Ticker: UFPT) experiences a pivotal moment as it undergoes significant changes in its leadership team. The company appoints Mitchell C. Rock as the new Chief Executive Officer, a mov…

Lantheus Holdings' LNTH-2513 Wins SNMMI's 2026 Image of the Year for DVT Diagnosis
Lantheus Holdings achieves significant milestone with its investigational PET imaging agent LNTH-2513 (18F-GP1), awarded SNMMI’s prestigious 2026 “Image of the Year.” The accolade highlights clinical…